Table 1 A table presenting some latest clinical studies of complement inhibitors in human

1

Adjuvant treatment with dexamethasone plus anti-C5 antibodies improves outcome of experimental pneumococcal meningitis: a randomized controlled trail

[104]

2

Atypical haemolytic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort

[105]

3

Therapeutic drug monitoring of eculizumab: rationale for an individualized dosing schedule

[106]

4

Complement inhibition for paroxysmal nocturnal hemoglobinuria: where we stand and where we are going

[107]

5

Inhibition of aberrant complement activation by a dimer of acetylsalicylic acid

[108]

6

Expanding role of therapeutic antibodies

[109]

7

A novel anticonvulsant mechanism via inhibition of complement receptor C5ar1 in murine epilepsy models

[110]

8

Current and future pharmacologic complement inhibitors

[111]

9

Successful use of eculizumab for treatment of an acute hemolytic reaction after ABO-incompatible red blood cell transfusion

[112]

10

Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention

[113]

11

Dissecting complement blockade for clinic use

[114]

12

Complement therapy in atypical haemolytic uraemic syndrome (aHUS)

[115]

13

Paroxysmal nocturnal haemoglobinuria and the age of therapeutic complement inhibition

[116]

14

Complement inhibitors in phase 1 and 2 clinical studies for immunological disorders

[117]

15

Inhibition of complement activation (eculizumab) in Guillain–Barre syndrome study

[118]

16

An open label clinical trial of complement inhibition in multifocal motor neuropathy

[119]

17

Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin

[120]

18

Complement activation and inhibition: a delicate balance

[121]

19

Complement-mediated ischemia–reperfusion injury: lessons learned from animal and clinical studies

[122]

20

Compstatin: a complement inhibitor on its way to clinical application

[123]

21

Shotgun proteomics implicates protease inhibition and complement activation in the anti-inflammatory properties of high density lipoprotein (HDL)

[124]

22

Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

[5]